Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 25, Issue 24, pp. 7303-7311
PubMed
Published By
Print ISSN
Online ISSN
History
- Received July 2, 2019
- Revision received September 19, 2019
- Accepted October 17, 2019
- Published first December 6, 2019.
Article Versions
- Previous version (December 6, 2019 - 00:05).
- You are viewing the most recent version of this article.
Copyright & Usage
©2019 American Association for Cancer Research.
Author Information
- Darren R. Hargrave1,*,
- Eric Bouffet2,
- Uri Tabori3,
- Alberto Broniscer4,
- Kenneth J. Cohen5,
- Jordan R. Hansford6,
- Birgit Geoerger7,
- Pooja Hingorani8,
- Ira J. Dunkel9,
- Mark W. Russo10,
- Lillian Tseng10,
- Kohinoor Dasgupta11,
- Eduard Gasal10,
- James A. Whitlock2, and
- Mark W. Kieran12
- 1Pediatric Oncology Unit, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
- 2Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
- 3Arthur and Sonia Labatt Brain Tumor Research Center, Division of Hematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
- 4Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
- 5The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Division of Pediatric Oncology, Baltimore, Maryland.
- 6Department of Pediatrics, The Royal Children's Hospital, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Victoria, Australia.
- 7Department of Childhood and Adolescent Oncology, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France.
- 8Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona.
- 9Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
- 10Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
- 11Novartis Healthcare Pvt. Ltd., Hyderabad, India.
- 12Harvard Medical School, Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.
- ↵*Corresponding Author:
Darren R. Hargrave, UCL Great Ormond Street Institute of Child Health, Great Ormond Street, London, WC1N 3JH, United Kingdom. Phone: 4420-7813-8525; Fax: 4420-7813-8588; E-mail: darren.hargrave{at}nhs.net
December 2019
Volume 25, Issue 24
Volume 25, Issue 24
Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
Jump to section
Advertisement